Induction of Passive Heymann Nephritis with Antibodies Specific for a Synthetic Peptide Derived from the Receptor-associated Protein

By Dontscho Kerjaschki,* Robert Ullrich,* Marcus Exner,* Robert A. Orlando,‡ and Marilyn G. Farquhar‡

From the *Institute of Clinical Pathology, Division of Ultrastructural Pathology and Cell Biology, University of Vienna, A-1090 Vienna, Austria; and ‡Division of Cellular and Molecular Medicine and Department of Pathology, University of California San Diego, La Jolla, California 92039

Summary

Passive Heymann nephritis (pHN) is an experimental rat model for human membranous glomerulopathy. In pHN, the formation of subepithelial immune deposits (ID) involves as antigenic targets the membrane glycoprotein gp330/megalin and the 44-kD receptor-associated protein (RAP). A single binding site for ID-inducing antibodies (Abs) was previously mapped to the 86 NH2-terminal amino acids of RAP (RAFT,86). To further narrow this epitope, Abs eluted from the glomeruli were immunoblotted on membranes that were loaded with overlapping synthetic peptides representing the amino acid sequence of RAP (SPOTs system). Two adjacent Ab-binding domains with the sequences PVRLAE (amino acids 39-44) and HSDLKIQE (amino acids 46-53), which were separated by a single L residue at amino acid 45, were detected. Rabbit Abs raised against synthetic peptides containing these domains individually (P31-44 and P46-53) failed to produce glomerular IDs. By contrast, Abs raised against a larger composite peptide (P31-53) induced IDs within 3 d that were firmly cross-linked to the glomerular basement membrane. These data suggest that Ab binding in vivo depends on the conformation of the antigenic target sequence that is preserved in the synthetic peptide P31-53, which covers the entire Ab-binding domain of RAP but not in its subdomains, P31-44 and P46-53. Collectively, these results locate the sole ID-inducing epitope of RAP to amino acids 39-53.

The design of therapies for autoimmune diseases is primarily based on identification of antigenic targets and induction of specific immune tolerance. Considerable progress has been made recently in several areas, such as allergic encephalomyelitis, in which epitopes were identified and duplicated by synthetic peptides (1, 2). However, relatively little is known about antigens of glomerular immune complex diseases despite their tendency to cause chronic renal failure. To learn more about the molecular pathogenesis of one relatively frequent glomerular immune disease, membranous glomerulopathy (3), we have investigated in detail an established experimental model in rats, i.e., passive Heymann nephritis (pHN) (4, 5). A hallmark of pHN is the presence of granular subepithelial immune deposits (IDs) that firmly adhere to the glomerular basement membrane (GBM) (6). The goal of our analysis of pHN is to eventually develop peptide-based therapies to specifically interfere with ID formation to provide a curative therapy for this model of membranous glomerulopathy.

In a series of investigations aimed at the identification of pHN antigens, we have used Abs eluted from glomeruli of diseased rats as the major tool, expecting that their specificities could guide us to the target antigen(s) and eventually to the pathogenic epitopes. This strategy led initially to identification of the >515-kD membrane glycoprotein megalin/gp330 (7, 8) and then to the 44-kD receptor-associated protein (RAP; 9, 10) formerly called C14 (11), which are associated together to form the Heymann nephritis antigenic complex (HNAC) (9). Search for pathogenic epitopes on HNAC has revealed one site that was originally thought to be localized on megalin (12), but was subsequently found to reside within the 86 NH2-terminal amino acids of RAP (RAFT,86) (12). Here, we further exploit the specificity of eluted glomerular Abs for the precise identification of the minimal antigenic target on RAP that is sufficient and competent for the induction of stable IDs.

Abbreviations used in this paper: FxIA, crude renal cortex fraction; HN, Heymann nephritis; HNAC, HN antigenic complex; GBM, glomerular basement membrane; ID, immune deposit; pHN, passive Heymann nephritis; PLP, paraformaldehyde-lysine-periodate; RAP, receptor-associated protein; RAP,86, NH2-terminal 86 amino acids of RAP.
**Materials and Methods**

*Antibodies.* Anti-RAP Abs were prepared by intradermal immunization of rabbits with 30 μg rRAP from the cDNA clone C14, as described (11). IgG fractions were prepared on protein A-Sepharose 4B (Pharmacia, Uppsala, Sweden) and affinity purified further on rRAP fusion protein coupled to a cyanogen bromide-Sepharose 4B column (Pharmacia) (11). Some IgG fractions were also affinity purified using a recombinant RAP1-86 (12).

*Induction of pHN and Elution of Glomerular IgG.* PHN was induced by ~25 mg i.v. of anti-rRAP IgG into 200 g male Lewis rats (Charles River, Sulzfeld, Germany). Eluted IgG was prepared from the isolated glomeruli of 50 rat kidneys with 100 mM citric buffer, pH 2.8 (7), and was concentrated on protein A-Sepharose. The use of experimental animals was authorized by the Austrian Ministry of Science.

*Preparation of Immobilized Overlapping Synthetic Peptides (SPOTs Assay).* The SPOTs technique allows simultaneous solid phase synthesis of a large number of peptides that can be probed by immunoblotting. SPOTs membranes (Imperial Chemical Industries, Cambridge, UK) were obtained with 96 preformed spots in which a single amino acid was conjugated to the cellulose matrix as an anchoring site for peptides. NH2-terminally acetylated peptides were synthesized manually by a miniaturized Fmoc-chemistry

---

**A**

**B**

| SPOT# | Composition of Spot | Results |
|-------|---------------------|---------|
|       | RAP amino acid      |         |
|       | 30                  |         |
|       | 40                  |         |
|       | 50                  |         |
|       | 55                  |         |
| 29    | WEAKRLHSPVRLAHELSDKIQERDELN | C-TERM. |
| 30    | EAKRLHSPV           | 0       |
| 31    | KAKRLHSPVR          | 0       |
| 32    | AKRLHSPVRL          | 0       |
| 33    | KRLHSPVRLA         | 0       |
| 34    | RHLHSPVRAE         | ++      |
| 35    | LHLHSPVRAEL        | ++      |
| 36    | HSLHSPVRAELH       | +++     |
| 37    | LSPVRAELHS         | +++     |
| 38    | SPVRAELHSD         | +++     |
| 39    | FVRAELHSDL         | ++      |
| 40    | VRALHSDLK          | +       |
| 41    | RLALHSDLKI         | 0       |
| 42    | LALHSDLKIQ         | 0       |
| 43    | AELHSDLKIQE        | +       |
| 44    | BHLHSDLKIQER       | ++      |
| 45    | LHSDLKIQERD        | ++      |
| 46    | HSSDLKIQERDE       | +       |
| 47    | SDLKIQERDEL        | 0       |
| 48    | DLKIQERDEL         | 0       |

---

**Figure 1.** (A) Sections of a SPOTs membrane containing 11-mer peptides with one amino acid overlap representing part of the RAP amino acid sequence. The membrane was immunoblotted with antibody eluted from the glomeruli of rats in which PHN was induced by IgG specific for rRAP. This antibody labeled specifically two clusters of spots, 34–40 and 43–46, but it failed to bind to spots, 25–33, 41 and 42, and 47–48. (B) In this interpretative table of the results of A, intensity of labeling of individual spots was arbitrarily scored +, ++, and ++++, and expressed by shading. The consensus amino acid sequence in each spot is marked by bold print. (C) Summary of results of SPOT experiments obtained with Abs specific for the glomerular eluate and for RAP1-86. Both Abs bind to amino acids 40–53 and apparently spare the L amino acid residue at 45.
Composition of Synthetic Peptides

Peptides Related to Binding Sites for ID Inducing Abs

| Peptide  | RAP amino acid | 30 | 40 | 45 | 50 | 53 |
|----------|----------------|----|----|----|----|----|
| Peptide P31-44 | WEKAKRLHLSVRLAEI | 1 | 1 | 1 | 1 | 1 |
| Peptide P46-53 | WEKAKRLHLSVRLAEI | 1 | 1 | 1 | 1 | 1 |
| Peptide P31-53 | WEKAKRLHLSVRLAEI | 1 | 1 | 1 | 1 | 1 |

Control Peptides

| Peptide  | Sequence (amino acids) |
|----------|------------------------|
| Peptide P55-64 | ERDELNWKKLK |
| Peptide P64-73 | KVGLGDKGE |
| Peptide P116-126 | PRLKMIHKAK |

Figure 2. Composition of synthetic peptides of various regions of RAP used for the generation of antibodies. The sequences of the peptides prepared are in bold print.

protocol, following the manufacturer's instructions. RAP-derived peptides were arranged as overlapping 11 mers with one amino acid offset, covering the entire sequence of RAP or RAP1-86.

Epitope Mapping by Immunoblotting on SPOTs Membranes. SPOTs membranes were immunoblotted with affinity-purified Abs specific for RAP or RAP1-86, or with eluted glomerular IgG (11, 12). Membranes were developed and erased before reuse according to the manufacturer's instructions (Imperial Chemical Industries). The amino acid sequences of Abs-binding domains were deduced from the common amino acid sequence shared by all labeled spots (Fig. 1).

Design and Production of Synthetic Peptides. Peptides were designed, two of which were extended by several amino acids towards the NH2 terminus of RAP beyond the region, to which eluted glomerular IgG bound in the SPOT analysis (see Fig. 2). Three peptides were produced: (a) P31-53 (KAKRLHLSVPVRALAELHSDLKIQE, amino acids 31–53); (b) P31-44 (KAKRLHLSVPVRALAELHSDLKIQE, amino acids 31–44); and (c) P46-53 (HSDLKIQE, amino acids 46–53). As controls, the irrelevant peptides P55-64, P64-73, and P116-126 from outside the antigenic regions of RAP were synthesized. Peptides were produced in an automatic peptide synthesizer (model 430A; Applied Biosystems, Inc., Foster City, CA). Peptides were purified to >95% purity by reverse-phase HPLC, and their sequences were analyzed in an Applied Biosystems gas phase sequencer at the Institute of Applied Microbiology, University of Agriculture (Vienna, Austria).

Preparation of Peptide-specific Abs. Synthetic peptides were coupled to a multiple antigenic peptide-polylysine matrix (13) and rabbits were immunized with 2.5 mg i.d. of each synthetic peptide, followed by two boosts with 1 mg peptide, each at 3 and 6 wk. Sera were collected at weekly intervals from the second boost onwards. IgG fractions were purified on protein A-Sepharose 4B and further affinity purified on CNBr-Sepharose coupled to the corresponding peptides (5–10 mg peptide/ml) as follows: 4 ml serum/ml affinity adsorbent were circulated for 12 h at 4°C, washed with 200 column volumes of PBS, and eluted with 20 mM glycine-HCl buffer, pH 2.8, 150 mM NaCl, 0.01% gelatin at 4°C. Eluted IgG was neutralized with 1 M Tris-HCl buffer, pH 8.0, dialyzed against 4 liters PBS, and concentrated with Aquacide II (Calbiochem, San Diego, CA) to 1–5 mg IgG/ml. P46-53 prepared as a multiple antigenic peptide or conjugated to KLH or BSA was not immunogenic in rabbits. P46-53-specific IgG was therefore prepared by affinity purification of anti-RAP IgG on a P46-53 CNBr column and used in lieu of Abs raised against the synthetic peptide.

Immunoblotting of Peptide-specific Antibodies. Rat kidney microvilli were prepared as described (7), and proteins were separated by SDS-PAGE and transferred onto nitrocellulose membranes. Lysates of isopropyl β-D-thiogalactoside (Sigma Chemical Co., St. Louis, MO)–induced Escherichia coli producing rRAP (11) were similarly transferred. Immunoblotting was performed with affinity-purified antipeptide Abs (~10 μg/ml) or with anti-
**SPOTs Assays with IgGs Specific for Synthetic Peptides**

| RAP amino acid | 30 | 40 | 45 | 50 | 55 |
|----------------|----|----|----|----|----|
| Anti-P$_{31-53}$ IgG | WEKAKRLHLSPVRLAEHSDDLQIERDEL |
| Anti-P$_{31-44}$ IgG | WEKAKRLHLSPVRLAEHSDDLQIERDEL |
| Anti-P$_{46-53}$ IgG | WEKAKRLHLSPVRLAEHSDDLQIERDEL |

**Results**

**Anti-RAP Abs and Eluted Glomerular Abs Bind Selectively to Two Adjacent Domains of RAP.** SPOTs membranes were prepared containing the primary sequence of RAP$_{1-86}$ disassembled into 72 overlapping 11-meric synthetic peptides (Fig. 1, A and B). This permitted simultaneous screening of all peptides for Ab-binding sites by immunoblotting that was initially performed with IgG eluted from glomeruli of rats injected with rRAP-specific Abs. Eluted IgG specifically labeled two clusters of spots, one corresponding to VRLAE (amino acids 40–44) and the second to HSDLQIERDEL (amino acids 46–53), which were separated by an L residue at amino acid 45 (Fig. 1, B and C). IgGs specific for rRAP and RAP$_{1-86}$ yielded similar results; however, both IgGs bound also to an additional P residue at amino acid 39 (Fig. 1 C). No labeling was observed in control experiments with irrelevant rabbit IgG or without primary Ab (data not shown).

These results indicate that the minimal binding sites on RAP of the most relevant Ab in this study, i.e., the eluted glomerular IgG, comprised a region of 14 amino acids with one intervening L residue. The accuracy of the NH$_2$-terminal border of the first Ab-binding region was limited by variation of ±1 amino acid in repeated immunoblots on multiple SPOTs membranes.

**Antipeptide Antibodies React Specifically with RAP.** Two synthetic peptides were designated P$_{31-44}$ and P$_{46-53}$ according to their amino acid composition. P$_{31-44}$ was extended beyond the binding region of eluted glomerular IgG by nine amino acids towards the NH$_2$ terminus of RAP to account for the variability of this border in the SPOTs assays. In addition, P$_{31-53}$, which covered both binding regions of eluted IgG, was synthesized (Fig. 2). Rabbit Abs specific for these peptides were prepared and affinity purified on CNBr peptide columns.

All antipeptide IgGs specifically and strongly reacted with RAP by immunoblotting on transfers of rRAP (Fig. 3) or on isolated microvillar fractions (Fig. 4). On SPOTs membranes, anti-P$_{31-44}$ IgG specifically labeled VRLAE (amino acids 39–44), and anti-P$_{46-53}$ IgG bound to SDLQIERDEL (amino acids 47–53). IgG raised against P$_{31-53}$ bound to PVRLAESDDLQIERDEL (amino acids 39–53) but not to amino acids 31–38 (Fig. 5). In control experiments, Abs raised to peptides distant from the NH$_2$ terminus of RAP bound only to their respective antigenic peptides (data not shown). These data provide evidence that Abs raised against synthetic peptides selectively bound to their respective sequences on RAP and mirrored the binding sites of IgG eluted from glomeruli.

**Antibodies Specific for Peptide P$_{1-15}$ Induce IDs That Firmly Attach to the GBM.** Abs produced against peptides P$_{31-44}$ and P$_{46-53}$ failed to induce IDs at 3 and 6 d after injection into rats (data not shown). By contrast, fine granular IDs were observed in the peripheral capillary walls of glomeruli after injection of anti-P$_{31-53}$ IgG (Fig. 6), in a pattern typical for HN. Some IgG was also detected within the mesangium. The glomerular pattern of IDs was confirmed by
Figure 6. Affinity-purified IgG specific for peptide P31-53 produces IDs 3 d after intravenous injection. IDs are visualized by direct immunofluorescence on semithin 1.5-μm frozen sections. There are numerous fine granular IDs in the peripheral glomerular capillary walls. The mesangium is also labeled in a granular pattern (M). Several large intracellular vacuoles of glomerular epithelial cells (arrowheads) contain rabbit IgG. ×1200.

These results indicate that IgGs specific for P31-53 form small IDs in peripheral glomerular capillary loops and that these IDs are firmly attached to the GBMs. Thus, this peptide-specific Ab is able to generate small IDs similar to those observed in pHN induced by IgGs specific for rRAP or RAP1-86 (11, 12).

Predictions of Homologies and Structure of the P31-53. P31-53 was found to contain twice a putative RT-1B1 MHC class II-binding motif, S x x x x x E (Fig. 10), thought to be important for generation of Abs in Lewis rats (17). Search for sequence similarities revealed no other significant resemblance of P31-53 to other rat proteins. Predictions of second-
ary structure with 70% certainty (16) indicated that P31-53 contains two helical regions at amino acids 31–35 and 41–53 connected by a short loop ranging from amino acids 36 to 40 (Fig. 11).

Discussion

Binding of antibodies in situ to specific epitopes on HNAC, a complex of RAP and megalin/gp330 (9, 18), triggers the formation of persistent IDs in the GBM (6). We and others have observed that Abs raised against rRAP form IDs after injection into rats (11, 19). We had previously identified a single ID-forming epitope at the NH2 terminus of RAP (RAP$_{1-86}$) (12) by the expression of a series of RAP cDNA deletion clones, raising of specific Abs, and probing of their ability to induce glomerular IDs. Here, we precisely determine the minimal amino acid sequence on RAP$_{1-86}$ that is required for the binding of
eluted glomerular IgG by mapping of IgG-binding domain(s) on overlapping synthetic peptides. In a second step, synthetic peptides that duplicated the Ab-binding domains were produced, and specific Abs were raised and probed for their capacity to induce stable glomerular IDs.

Mapping of binding sites of eluted Abs on a large number of RAP1-86-derived synthetic peptides was performed by SPOTs assays. The results provided evidence for two adjacent Ab-binding domains within the sequences VR\-LAELH (amino acids 40–44) and HSDLKIQE (amino acids 46–53), with an apparent inaccuracy of ± 1 amino acid at the NH2-terminal border of the first binding site. These findings raised the possibility that RAP amino acids 40–53 were involved in ID formation in vivo and that appropriate peptide-specific Abs could induce IDs. At first, peptides P31-44 and P46-53 were synthesized, and specific rabbit Abs were prepared which, however, failed to form IDs when injected into rats. Therefore, a large peptide spanning both P31-44 and P46-53 was designed and designated P31-53. Intravenous injection of Abs raised against this peptide promptly induced small IDs in the peripheral capillary walls of glomeruli. Moreover, these IDs strongly adhered to the GBM in cell-free preparations of GBMs. Thus, in most respects, IDs produced by injection of anti-P31-53 IgG were similar to those induced by conventional Abs (6).

These data indicate that anti-P31-53 IgG binds in vitro and in vivo to the same amino acid sequence of RAP as Abs eluted from glomeruli of rats with pHN. Intriguingly, Abs raised against P31-44 and P46-53 failed to produce IDs when injected into rats. It is possible that P31-53 acts as a composite peptide that mimics a natural structural epitope by simultaneously presenting two linked antigenic peptides to the immune system. Thus, while Abs raised against the composite peptide bind in vivo to the native protein, Abs raised against individual smaller peptides bind to their respective amino acid sequences only in vitro in unfolded proteins. A similar situation was recently observed for the proliferating cell nuclear antigen in lupus erythematosus (20). Abs specific for individual synthetic peptides modeled after immunogenic domains failed to bind in vivo. Abs raised against a dimer of these peptides, however, readily bound to their nuclear antigen in vivo, presumably because this composite peptide antigen resembled the corresponding conformation-dependent natural epitope. It remains to be seen to which extent the structural predictions of a helix-loop-helix motif in the region of the P31-53 peptide are related to the topography of this epitope on RAP.

HN is characterized by relatively large IDs and by proteinuria. Although large amounts of Ab specific for P31-53 were injected into rats, the IDs obtained were considerably smaller than those induced by conventional Abs, such as antimegalin/gp330 IgG (6, 21). It is possible that anti-P31-53 IgG serves only as nidus for ID formation, and that additional Abs directed against epitopes on megalin bind subsequently. We have provided evidence that antimegalin Abs without reactivity to RAP induce IDs (21), and one epitope on megalin was recently identified on the fifth cystine-rich repeat of the second LDL receptor-like domain of megalin (22). Thus, while the RAP epitope identified in this study provides a single nidus for the formation of an initial ID, it is clear that additional epitopes on megalin must be operative to yield IDs of the large sizes typically found in passive and active HN. Lack of proteinuria after injection of anti-P31-53 IgG is presumably caused by the absence of C5b-9-activating Abs specific for glycolipids that were recently identified as components of anti-FxA IgG (23).

In a next step, it will be of interest to attempt to produce active HN by immunization of Lewis rats with synthetic peptides, which may be facilitated by two putative MHC class II peptide--binding motifs specific for Lewis rats (17) within P31-53. Further on, attempts to interfere with the immunologic basis of the disease by use of synthetic peptides will be possible. One example indicating the feasibility of this approach is derived from studies on experimental murine interstitial nephritis (24), which was ameliorated by specific synthetic peptides.
Collectively, the results of this study provide evidence for a presumably structural epitope on RAP that is responsible for the formation of subepithelial IDs in pHN and spans 14 amino acids. These findings are also the first example of induction of glomerular IDs with Abs specific for synthetic peptides modeled after natural Ab-binding sites.

We are indebted to Dr. Russell Doolittle (Center for Molecular Genetics, UCSD, La Jolla, CA) for invaluable advice on computer predictions of antigenic sites, design of synthetic peptides, and interpretation of the data. We acknowledge the expert technical help of Ms. Helga Poczewski and Regina Liebl.

This work was supported by the Fonds zur Förderung der Wissenschaftlichen Forschung (SFB “Tissue Damage and Repair” to D. Kerjaschki), F32-DK 08885 (to R.A. Orlando), and National Institutes of Health grant DK 17724 (to M.G. Farquhar).

Address correspondence to Dr. Dentscho Kerjaschki, Institute for Clinical Pathology, AKH, University of Vienna, Währinger Gürtel 18-20, A-1090 Vienna, Austria.

Received for publication 8 February 1996 and in revised form 21 February 1996.

References

1. Clayton, J.P., G.M. Gammon, D.G. Ando, D.H. Kono, L. Hood, and E.E. Sercarz. 1989. Peptide-specific prevention of experimental allergic encephalomyelitis. J. Exp. Med. 169: 1681–1691.
2. Zamvil, S.S., D.J. Mitchell, A.C. Moore, L. Kitamura, L. Steinmann, and J.B. Rothbard. 1986. T-cell epitope of the autoantigen myelin basic protein that induces encephalomyelitis. Nature (Lond.). 324:258–269.
3. Schwartz, M.M. 1992. Membranous glomerulonephritis. In Pathology of the Kidney. R.H. H histinall, editor. Little, Brown and Co., Boston, MA. 559–626.
4. Andres, G., J.R. Brentjens, P.R.B. Caldwell, G. Camussi, and S. Matsu. 1986. Biology of disease: formation of immune deposits and disease. Lab Invest. 55:510–520.
5. Farquhar, M.G., A. Saito, D. Kerjaschki, and R. Orlando. 1995. The Heymann nephritis antigenic complex: megalin (gp330) and RAP. J. Am. Soc. Nephrol. 6:35–47.
6. Kerjaschki, D., A. Miettinen, and M.G. Farquhar. 1987. Initial events in the formation of IDs in passive Heymann nephritis: Gp330-anti gp330 immune complexes form in epithelial coated pits and rapidly become attached to the GBM. J. Exp. Med. 166:109–128.
7. Kerjaschki, D., and M.G. Farquhar. 1982. Identification of a membrane glycoprotein from kidney brush border as the pathogenic antigen of Heymann’s nephritis. Proc. Natl. Acad. Sci. USA. 79:5557–5561.
8. Saito, A., S. Pietromonaco, A.K.C. Loo, and M.G. Farquhar. 1994. Complete cloning and sequencing of rat gp330/megalin, a distinctive member of the low density lipoprotein receptor gene family. Proc. Natl. Acad. Sci. USA. 91:9725–9729.
9. Farquhar, M.G., D. Kerjaschki, M. Lundstrom, and R. Orlando. 1994. Gp330 and RAP: the Heymann nephritis antigenic complex. Am. J. Physiol. 173:1–15.
10. Williams, S.E., M.Z. Kounnas, L.M. Argraves, S. Argraves, and D.K. Strickland. 1994. The α2-macroglobulin receptor/low density lipoprotein receptor related protein and the receptor associated protein: an overview. Ann. NY Acad. Sci. 739:1–13.
11. Pietromonaco, S.D., D. Kerjaschki, S. Binder, R. Ullrich, and M.G. Farquhar. 1990. Molecular cloning of a cDNA encoding a major pathogenic domain of the Heymann nephritis antigen gp330. Proc. Natl. Acad. Sci. USA. 87:1811–1815.
12. Kerjaschki, D., R. Ullrich, S. Pietromonaco, K. Diem, R.A. Orlando, and M.G. Farquhar. 1992. Identification of a pathogenic epitope involved in the initiation of Heymann nephritis. Proc. Natl. Acad. Sci. USA. 89:11179–11183.
13. Tam, J.P. 1988. Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc. Natl. Acad. Sci. USA. 85:5409–5413.
14. McLean, J.W., and P.K. Nakane. 1974. Periodate-lysine-paraformaldehyde fixative: a new fixative for electron microscopy. J. Histochem. Cytochem. 22:1077–1083.

15. Neale, T.J., P.P. Ojha, M. Exner, H. Poczewski, B. Rueger, J.L. Witztum, P. Davis, and D. Kerjaschki. 1994. Proteinuria in passive Heymann nephritis is associated with lipid peroxidation and formation of adducts on type IV collagen. J. Clin. Invest. 94:1577–1584.

16. Rost, B., and C. Sander. 1993. Prediction of protein structure at better than 70% accuracy. J. Mol. Biol. 232:584–599.

17. Zhao, W., K.W. Wegmann, J.L. Trotter, K. Ueno, and W.F. Hickey. 1994. Identification of an N-terminally acetylated encephalitogenic epitope in myelin proteolipid apoprotein for Lewis rats. J. Immunol. 153:901–909.

18. Orlando, R.A., D. Kerjaschki, H. Kurihara, D. Biemensderfer, and M.G. Farquhar. 1992. gp330 associates with a 44-kD protein in the rat kidney to form the Heymann nephritis antigenic complex. Proc. Natl. Acad. Sci. USA. 89:6698–6702.

19. Huang, J., and S.P. Makker. 1995. Role of receptor-associated 39/45 kD protein in active Heymann nephritis. Kidney Int. 47:432–441.

20. Muro, Y., W.M. Tsai, R. Houghten, and E.M. Tan. 1994. Synthetic compound peptide stimulating antigenicity of conformation-dependent autoepitope. J. Biol. Chem. 269:18529–18534.

21. Orlando, R.A., D. Kerjaschki, and M.G. Farquhar. 1995. Megalin (gp330) possesses antigenic epitopes capable of inducing passive Heymann nephritis independent of the nephritogenic epitope on RAP. J. Am. Soc. Nephrol. 6:61–67.

22. Saito, A., R. Ullrich, D. Kerjaschki, and M.G. Farquhar. 1995. Mapping pathogenic epitopes of rat megalin (gp330), a major Heymann nephritis antigen. J. Am. Soc. Nephrol. 6:853 (Abstr.).

23. Susani, M., M. Schulze, M. Exner, and D. Kerjaschki. 1994. Antibodies to glycolipids activate complement and promote proteinuria in passive Heymann nephritis. Am. J. Pathol. 144:807–819.

24. Neilson, E.G., M.J. Sun, C.J. Kelly, W.H. Hines, T.P. Haverty, M.D. Clayman, and N.E. Cooke. 1991. Molecular characterization of a major nephritogenic domain in the autoantigen of anti-tubular basement membrane disease. Proc. Natl. Acad. Sci. USA. 88:2006–2010.